Pulmonary Hypertension Program | Research and Innovation

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Contact the Pulmonary Hypertension Program

Our team in the Pulmonary Hypertension Program at Boston Children's Hospital is actively involved in therapeutic trials of new therapies for pulmonary hypertension. We’ve participated in prospective trials of inhaled nitric oxide, sildenafil, bosentan and ambrisentan. Our current therapeutic trials include:

  • evaluation of a new, more efficient way of delivering inhaled iloprost
  • study of the long-term effects of sildenafil and ambrisentan

We are also exploring new ways of evaluating the lung’s blood vessels to help us better design therapy.

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close